Saudi FDA Approval Status of Upadacitinib for Alopecia Areata
The provided evidence does not contain any information regarding Saudi Food and Drug Authority (Saudi FDA) approval status for upadacitinib in alopecia areata. The available evidence only addresses U.S. FDA approval status and clinical data.
What the Evidence Shows About Regulatory Approval
U.S. FDA Approval Status
- Upadacitinib is NOT currently approved by the U.S. FDA for alopecia areata 1.
- The FDA has approved upadacitinib for other indications including rheumatoid arthritis and atopic dermatitis in patients aged 12 years and older 1.
- The American Academy of Dermatology notes that JAK inhibitors including upadacitinib are "approved or under investigation" for multiple dermatologic conditions including alopecia areata, but this does not indicate current FDA approval for AA specifically 2.
Other JAK Inhibitors Approved for Alopecia Areata
- Baricitinib and ritlecitinib are the FDA-approved oral JAK inhibitors for severe alopecia areata in adults 3.
- Deuruxolitinib was approved by the U.S. FDA in July 2024 for severe AA in adults 3.
Clinical Evidence for Upadacitinib in Alopecia Areata
Despite lack of formal approval, substantial clinical evidence supports efficacy:
Efficacy Data
- A scoping review of 64 AA patients treated with upadacitinib (15-45 mg daily) showed most patients experienced substantial or complete hair regrowth within 1-4 months 4.
- The medication demonstrated effectiveness across severe subtypes including alopecia universalis (n=28), ophiasis (n=15), and alopecia totalis (n=8) 4.
- In adolescents with severe AA, the median Severity of Alopecia Tool score dropped by 58.08% after 6 months of treatment with 15 mg daily 5.
Safety Profile
- Upadacitinib was generally well tolerated with mild adverse events including transient acneiform eruptions, leukopenia, and creatine phosphokinase elevations 4.
- No severe adverse events were detected in adolescent case series 5.
- The FDA has issued class-wide warnings for JAK inhibitors regarding increased risk of serious cardiovascular events, malignancy, thromboembolism, and mortality based on data from other JAK inhibitors in different patient populations 2.
Ongoing Research
- A U.S. Phase 3 clinical trial (M23-716) is currently assessing long-term efficacy and safety of upadacitinib for AA 4.
- A real-world observational study in China (NCT06573593) is comparing upadacitinib with other JAK inhibitors 4.
Critical Gap in Evidence
The provided evidence contains no documentation regarding Saudi FDA approval status, regulatory submissions, or approval timelines for upadacitinib in alopecia areata. To determine Saudi FDA approval status, you would need to:
- Consult the Saudi Food and Drug Authority official database directly
- Contact the manufacturer (AbbVie) regarding Saudi regulatory status
- Review Saudi-specific regulatory announcements